Home > Dermatology > EADV 2019 > Late-Breaking News > No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD

No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD

Presented By
Prof. Regina Fölster-Holst, University Medical Center Schleswig-Holstein, Germany
Conference
EADV 2019
Trial
APPLES
Children that regularly use the topical calcineurin inhibitor tacrolimus over more than 10 years face no elevated risk of cancer. This was the result of an observational study including more than 44,000 patient-years of follow-up [1]. “Atopic dermatitis is a chronic disease requiring long-term treatment. Therefore, we need prospective safety studies to evaluate the cancer risk,” said Prof. Regina Fölster-Holst (University Medical Center Schleswig-Holstein, Germany). A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis (APPLES™) is an international observational study designed to address the possibility of increased lymphoma or other cancer risk in patients treated long-term with topical calcineurin inhibitors. The primary outcome was occurrence of any malignancy. In addition, incidences of lymphoma or cutaneous malignant melanoma were assessed. Standardised incid...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on